Enabling the next-generation of bioactive small molecules with our metagenomic and whole-genome database collections and strain engineering capabilities.
Drug developers seek novel, diverse bioactive molecules, but identifying, isolating, producing, and derivatizing natural compounds is often slow and inefficient. Using AI-driven tools, we mine our genomic databases to uncover next-generation small molecules for ADC payloads, anti-infectives, adjuvants, and more. Our expertise in biosynthetic route development and strain engineering enables efficient material generation, from prototype to scalable processes.
Project Spotlight
We were thrilled to announce our award of a 5-year contract alongside SaponiQx, totaling up to $31 million including program options, to discover and develop next-generation vaccine adjuvants.
Terabytes of data in our databases
Predicted natural products
Predicted protein sequences
Overlap with public sequence databases
By partnering with Ginkgo Bioworks, a global leader in organism engineering, we are greatly increasing our ability to develop essential medicines at the speed and scale necessary to drive change in global pharma supply chains.
- Antheia
